533 related articles for article (PubMed ID: 37046001)
1. Dynamics and specificities of T cells in cancer immunotherapy.
Oliveira G; Wu CJ
Nat Rev Cancer; 2023 May; 23(5):295-316. PubMed ID: 37046001
[TBL] [Abstract][Full Text] [Related]
2. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
3. Phenotype, specificity and avidity of antitumour CD8
Oliveira G; Stromhaug K; Klaeger S; Kula T; Frederick DT; Le PM; Forman J; Huang T; Li S; Zhang W; Xu Q; Cieri N; Clauser KR; Shukla SA; Neuberg D; Justesen S; MacBeath G; Carr SA; Fritsch EF; Hacohen N; Sade-Feldman M; Livak KJ; Boland GM; Ott PA; Keskin DB; Wu CJ
Nature; 2021 Aug; 596(7870):119-125. PubMed ID: 34290406
[TBL] [Abstract][Full Text] [Related]
4. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy.
Joshi K; Milighetti M; Chain BM
Curr Opin Immunol; 2022 Feb; 74():1-8. PubMed ID: 34454284
[TBL] [Abstract][Full Text] [Related]
5. Helper innate lymphoid cells as cell therapy for cancer.
Magnusson FC; Bahhar I
Immunology; 2023 Apr; 168(4):569-579. PubMed ID: 36288454
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of T cell exhaustion for cancer immunotherapy.
Chow A; Perica K; Klebanoff CA; Wolchok JD
Nat Rev Clin Oncol; 2022 Dec; 19(12):775-790. PubMed ID: 36216928
[TBL] [Abstract][Full Text] [Related]
8. Emerging Strategies in TCR-Engineered T Cells.
Wei F; Cheng XX; Xue JZ; Xue SA
Front Immunol; 2022; 13():850358. PubMed ID: 35432319
[TBL] [Abstract][Full Text] [Related]
9. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
10. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity.
Zhang S; Zhang X; Yang H; Liang T; Bai X
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189022. PubMed ID: 37993001
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
12. The Interplay between T Cells and Cancer: The Basis of Immunotherapy.
Chen C; Liu X; Chang CY; Wang HY; Wang RF
Genes (Basel); 2023 Apr; 14(5):. PubMed ID: 37239368
[TBL] [Abstract][Full Text] [Related]
13. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
14. Metabolic barriers to cancer immunotherapy.
DePeaux K; Delgoffe GM
Nat Rev Immunol; 2021 Dec; 21(12):785-797. PubMed ID: 33927375
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis: a
Lee YG; Yang N; Chun I; Porazzi P; Carturan A; Paruzzo L; Sauter CT; Guruprasad P; Pajarillo R; Ruella M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37055217
[TBL] [Abstract][Full Text] [Related]
16. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
17. Cell Fate Reprogramming in the Era of Cancer Immunotherapy.
Zimmermannova O; Caiado I; Ferreira AG; Pereira CF
Front Immunol; 2021; 12():714822. PubMed ID: 34367185
[TBL] [Abstract][Full Text] [Related]
18. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
